Forbes November 16, 2024
There are no routine screenings for ovarian cancer for women. Yes, ovarian cancer is rare, representing 1% of new cancer diagnoses every year in the U.S. But, it’s a serious disease as only half of the nearly 20,000 women diagnosed each year survive past 5 years. That’s quite low as compared with breast cancer, where the 5-year survival rate is over 90%.
Scientists at Cancer Research UK were recently awarded £600,000 to develop the first ovarian cancer vaccine, called OvarianVax. Medical oncologist and immunologist Dr. Matthew Block from the Mayo Clinic is working to develop an ovarian cancer vaccine using engineered white blood cells from patients with ovarian cancer. The vaccine will target a protein called folate receptor alpha that...
Today's Sponsors
Today's Sponsor